Cancer Drug Resistance
All Journals
Search Log In
Home Articles Special Issues Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Home Articles Special Issues Volumes Webinars Videos

fig4

From:  Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma
Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Figure 4. Lymphocyte levels and outcomes with patients classified by tumor localization: (A) lymphocyte level diagram box depending on tumor localization; (B) diagram box of overall survival from BVZ administration depending on tumor localization. BVZ: bevacizumab

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2024 OAE Publishing Inc., except certain content provided by third parties